| Hernandes, Mauro |
OPTION TREAT, NCT05920005: Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension |
|
|
| Recruiting | 3 | 698 | RoW | candesartan cilexetil + chlorthalidone + amlodipine, Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg) | Hospital Israelita Albert Einstein, Libbs Farmacêutica LTDA | Hypertension | 12/23 | 07/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
| Takahashi, Toshiyuki |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
| Saporito, Wladimir Faustino |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial |
|
|
| Completed | 3 | 731 | US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF) | 07/24 | 07/24 | | |
|
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
| Widener, Nancy |
| Recruiting | 3 | 1655 | Europe, Canada, Japan, US, RoW | Abelacimab, MAA868, Apixaban, Eliquis | Anthos Therapeutics, Inc., Itreas | Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism | 12/26 | 02/27 | | |
| Recruiting | 3 | 1020 | Europe, Canada, US, RoW | Abelacimab, MAA868, Dalteparin, Fragmin | Anthos Therapeutics, Inc., Itreas | Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism | 12/26 | 02/27 | | |
| Haraguchi, Mikiko |
NCT05326230: A Clinical Study of the Paradise™ Renal Denervation System in Patients with Hypertension (RADIANCE-HTN DUO) |
|
|
| Recruiting | N/A | 154 | Japan | Paradise™ (PRDS-001) Renal Denervation Ultrasound System, Renal Angiogram/Renal Denervation, Renal Angiogram | Otsuka Medical Devices Co., Ltd. Japan | Hypertension, Vascular Diseases, Cardiovascular Diseases | 12/25 | 12/29 | | |
NCT05759819: Evaluate the Efficacy and Safety of the Cilostazol-coated BioMimics 3D Stent System in Patients With Peripheral Arterial Occlusive Disease |
|
|
| Active, not recruiting | N/A | 24 | Japan | Standard stenting | Otsuka Medical Devices Co., Ltd. Japan | Peripheral Arterial Disease | 12/24 | 12/26 | | |
| Ishinabe, Kentaro |
NCT06589505: Software as a Medical Device for the Treatment of Patients With PTSD |
|
|
| Recruiting | 2/3 | 52 | Japan | Software as a Medical Device | Otsuka Medical Devices Co., Ltd. Japan, Otsuka Pharmaceutical Co., Ltd. | Post-Traumatic Stress Disorder, PTSD | 01/28 | 01/28 | | |
NCT05326230: A Clinical Study of the Paradise™ Renal Denervation System in Patients with Hypertension (RADIANCE-HTN DUO) |
|
|
| Recruiting | N/A | 154 | Japan | Paradise™ (PRDS-001) Renal Denervation Ultrasound System, Renal Angiogram/Renal Denervation, Renal Angiogram | Otsuka Medical Devices Co., Ltd. Japan | Hypertension, Vascular Diseases, Cardiovascular Diseases | 12/25 | 12/29 | | |
